Remote-controlled therapeutics,
now nonfiction.

Richard is a co-founder of Nonfiction, where he is developing magnetogenetic tools to enable precise, noninvasive control of protein therapeutics using modest magnetic fields. Richard Fuisz is a co-inventor of several patents, including several related to magnetogenetic control of protein therapeutics. Prior to Nonfiction Labs, Richard founded DNA-synthesis company Templa Nucleics, was a founding team member of Arcadia Science and FutureHouse. Richard received his B.S. in Bioengineering at Stanford University.

Maria is a co-founder of Nonfiction, where she is advancing magnetogenetic control of protein therapeutics using modest (~10 mT) magnetic fields. Prior to Nonfiction, María discovered that fluorescent proteins respond to magnetic fields, and engineered the first large-response magneto-protein, MagLOV. Earlier, she completed her post-doctoral work with George Patterson, building advanced microscopy systems and marrying probe design with cutting-edge imaging.

Rebecca develops next-generation light- and magnetically-controlled proteins, drawing on expertise at the intersection of protein engineering, fluorescence microscopy, and patterned-light stimulation. Prior to Nonfiction Labs, Rebecca built all-optical electrophysiology platforms in Adam Cohen’s laboratory at Harvard and contributed to the discovery of magnetic field control of fluorescent proteins in Andrew York’s laboratory at Calico. Rebecca received her Ph.D. from Harvard University.

Regina develops magnetically controlled protein systems for precise, noninvasive biological control. Prior to Nonfiction, Regina worked as a postdoctoral researcher at the Max Planck Institute for Biology in Tübingen, Germany, where she brought expertise in gene regulation and molecular engineering as a trained plant epigeneticist. Regina received a dual Ph.D. from Universidad Nacional del Litoral (Argentina) and TU Dresden (Germany).

María Clara works on protein screening systems to support the selection and optimization of MagnetoTherapeutics at Nonfiction. Prior to Nonfiction, María Clara worked on protein function, autophagy, and metabolic regulation using Drosophila as an in vivo model. She gained experience in fluorescent reporter development during research stays at Harvard Medical School (Perrimon lab) and Calico. María Clara received her Ph.D. and completed postdoctoral training at CONICET–UNL in Argentina.

Andrés leads laboratory operations for Nonfiction’s Argentina site, overseeing facility build-out, equipment procurement, and local team coordination. His research spans over 20 years in genetics, cellular, and molecular biology. Andrés received his Ph.D. from the Instituto Leloir / Universidad de Buenos Aires and completed postdoctoral training at IRB Barcelona.

Paula optimizes engineered protein constructs at Nonfiction Labs, leveraging large-scale site-directed mutagenesis to enhance enzymatic magnetogenetic control. Prior to Nonfiction Labs, Paula conducted research as a chronobiologist examining how circadian proteins influence glioblastoma growth, uncovering chronochemotherapy strategies for brain tumors. Paula received her Ph.D. in biotechnology with expertise in circadian biology and cancer metabolism.

Pablo designs, produces, and tests magbodies that target novel targets, contributing to the development of Nonfiction’s therapeutic asset pipeline. Prior to Nonfiction Labs, Pablo completed postdoctoral training in protein nanobioengineering at IPROBYQ (CONICET), specializing in recombinant protein design and scale-up. Pablo received his Ph.D. in Biological Sciences from Universidad Nacional del Litoral.

Nadia implements and optimizes laboratory techniques at Nonfiction Labs, including protein production and purification, ELISA assays, and technical support across research and development activities. Prior to Nonfiction Labs, Nadia developed expertise in molecular biology, cell culture, and protein engineering through her doctoral research. Nadia received her Ph.D. in Biological Sciences.

María Jesús designs, produces, and tests magbodies that target novel targets, contributing to the development of Nonfiction’s therapeutic asset pipeline. Prior to Nonfiction Labs, María Jesús worked extensively on therapeutic protein engineering, including expression in mammalian cell systems and monoclonal antibody production, purification, and characterization. María Jesús received her Ph.D. in Biological Sciences from Universidad Nacional del Litoral.

Paige screens novel magnetogenetic binders and proteins, scaling our screening capabilities and developing robust manufacturing protocols. Prior to Nonfiction Labs, Paige worked on IgE monoclonal antibody (mAb) discovery, developing novel therapeutic platforms for immune-mediated diseases. Her research background includes extensive work in genetic engineering and protein characterization assays. Paige holds a background in molecular biology with specialization in therapeutic antibody development.

Andrew advises Nonfiction Labs on imaging techniques and magnetogenetics. Previously, Andrew led a research group at Calico Life Sciences where he co-discovered magnetic field control of fluorescent proteins. Andrew has made significant contributions to the field of magnetogenetics, including the co-discovery of magnetic field control of fluorescent proteins and contributions in optical physics, super-resolution imaging, and light-matter interactions.